Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombotic Microangiopathies | 9 | 2024 | 52 | 3.640 |
Why?
|
| Complement Pathway, Alternative | 6 | 2019 | 14 | 2.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2024 | 1198 | 1.880 |
Why?
|
| Pulmonary Embolism | 4 | 2024 | 177 | 1.690 |
Why?
|
| Thrombosis | 9 | 2024 | 519 | 1.480 |
Why?
|
| Venous Thromboembolism | 3 | 2025 | 165 | 1.110 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 4 | 2022 | 53 | 1.080 |
Why?
|
| Kidney Glomerulus | 2 | 2018 | 78 | 1.070 |
Why?
|
| Anticoagulants | 6 | 2025 | 589 | 1.040 |
Why?
|
| Endothelial Cells | 4 | 2018 | 521 | 0.960 |
Why?
|
| Hemorrhage | 2 | 2023 | 468 | 0.810 |
Why?
|
| Plasma Exchange | 2 | 2024 | 84 | 0.780 |
Why?
|
| Warfarin | 1 | 2023 | 119 | 0.780 |
Why?
|
| Complement Activation | 2 | 2019 | 52 | 0.750 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 338 | 0.680 |
Why?
|
| Complement C3b | 1 | 2019 | 7 | 0.670 |
Why?
|
| Complement Factor B | 1 | 2019 | 11 | 0.670 |
Why?
|
| Patient Care Team | 1 | 2024 | 542 | 0.650 |
Why?
|
| Microvessels | 2 | 2020 | 56 | 0.620 |
Why?
|
| Child | 22 | 2025 | 24374 | 0.590 |
Why?
|
| Endothelium, Vascular | 2 | 2020 | 520 | 0.510 |
Why?
|
| Protein C | 1 | 2015 | 21 | 0.510 |
Why?
|
| Biomarkers | 3 | 2024 | 3063 | 0.500 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 503 | 0.490 |
Why?
|
| von Willebrand Factor | 4 | 2023 | 196 | 0.380 |
Why?
|
| Vena Cava, Inferior | 2 | 2021 | 103 | 0.340 |
Why?
|
| Humans | 33 | 2025 | 124618 | 0.340 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 727 | 0.340 |
Why?
|
| Venous Thrombosis | 2 | 2022 | 183 | 0.330 |
Why?
|
| Hemolytic-Uremic Syndrome | 2 | 2022 | 35 | 0.320 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2021 | 115 | 0.310 |
Why?
|
| Alligators and Crocodiles | 1 | 2008 | 1 | 0.310 |
Why?
|
| Amputation, Traumatic | 1 | 2008 | 10 | 0.310 |
Why?
|
| Arm Injuries | 1 | 2008 | 13 | 0.310 |
Why?
|
| Adolescent | 11 | 2024 | 19278 | 0.310 |
Why?
|
| Bites and Stings | 1 | 2008 | 29 | 0.310 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 3 | 2018 | 9 | 0.310 |
Why?
|
| Debridement | 1 | 2008 | 89 | 0.300 |
Why?
|
| Retrospective Studies | 10 | 2024 | 16317 | 0.300 |
Why?
|
| Brain | 1 | 2018 | 2983 | 0.260 |
Why?
|
| Coronavirus Infections | 2 | 2022 | 358 | 0.250 |
Why?
|
| Pneumonia, Viral | 2 | 2022 | 372 | 0.250 |
Why?
|
| Child, Preschool | 7 | 2024 | 14009 | 0.250 |
Why?
|
| Thrombolytic Therapy | 3 | 2024 | 209 | 0.240 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2018 | 681 | 0.220 |
Why?
|
| Infant | 7 | 2024 | 12468 | 0.220 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2022 | 176 | 0.210 |
Why?
|
| International Normalized Ratio | 1 | 2023 | 41 | 0.210 |
Why?
|
| Adult | 8 | 2024 | 29440 | 0.210 |
Why?
|
| Blood Coagulation Disorders | 1 | 2023 | 103 | 0.200 |
Why?
|
| Health Information Systems | 1 | 2022 | 32 | 0.200 |
Why?
|
| Thromboembolism | 1 | 2022 | 89 | 0.190 |
Why?
|
| Aortic Diseases | 2 | 2024 | 198 | 0.180 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 317 | 0.180 |
Why?
|
| Lung Diseases | 1 | 2024 | 384 | 0.180 |
Why?
|
| Male | 11 | 2024 | 61200 | 0.160 |
Why?
|
| Lower Extremity | 1 | 2021 | 187 | 0.160 |
Why?
|
| Immunoassay | 2 | 2015 | 130 | 0.150 |
Why?
|
| Complement Factor H | 2 | 2015 | 21 | 0.150 |
Why?
|
| Receptor, Anaphylatoxin C5a | 1 | 2018 | 12 | 0.150 |
Why?
|
| Complement C3a | 1 | 2018 | 19 | 0.150 |
Why?
|
| Inpatients | 1 | 2022 | 496 | 0.150 |
Why?
|
| Complement C5a | 1 | 2018 | 24 | 0.150 |
Why?
|
| Receptors, Complement | 1 | 2018 | 32 | 0.150 |
Why?
|
| Microscopy, Fluorescence | 2 | 2015 | 326 | 0.140 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 203 | 0.140 |
Why?
|
| Young Adult | 5 | 2024 | 9014 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2008 | 2426 | 0.140 |
Why?
|
| Pediatric Obesity | 1 | 2022 | 383 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.130 |
Why?
|
| Female | 9 | 2024 | 66495 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2023 | 4795 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1322 | 0.130 |
Why?
|
| Hospitalization | 1 | 2024 | 1777 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2816 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 636 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 457 | 0.120 |
Why?
|
| Risk Factors | 3 | 2024 | 10270 | 0.120 |
Why?
|
| Muscle Proteins | 1 | 2018 | 417 | 0.120 |
Why?
|
| Platelet Activation | 1 | 2015 | 71 | 0.120 |
Why?
|
| Platelet Aggregation | 1 | 2015 | 120 | 0.120 |
Why?
|
| Anemia, Aplastic | 1 | 2015 | 59 | 0.120 |
Why?
|
| Fibrinogen | 1 | 2015 | 154 | 0.110 |
Why?
|
| Prognosis | 2 | 2023 | 4625 | 0.110 |
Why?
|
| Aorta, Thoracic | 1 | 2019 | 528 | 0.110 |
Why?
|
| Cytoplasm | 1 | 2015 | 290 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2015 | 420 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 504 | 0.110 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2015 | 140 | 0.110 |
Why?
|
| Hemostasis | 2 | 2025 | 69 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2015 | 797 | 0.110 |
Why?
|
| Gene Expression | 1 | 2018 | 1562 | 0.100 |
Why?
|
| Bone Marrow | 1 | 2015 | 324 | 0.100 |
Why?
|
| Models, Biological | 1 | 2018 | 1459 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3281 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3040 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 647 | 0.090 |
Why?
|
| Inflammation | 1 | 2018 | 1431 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5145 | 0.090 |
Why?
|
| Consensus | 2 | 2023 | 646 | 0.080 |
Why?
|
| Transcriptome | 1 | 2015 | 952 | 0.080 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8191 | 0.080 |
Why?
|
| Suture Techniques | 1 | 2008 | 196 | 0.070 |
Why?
|
| Hematology | 1 | 2025 | 38 | 0.060 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2023 | 35 | 0.050 |
Why?
|
| Thrombectomy | 1 | 2024 | 106 | 0.050 |
Why?
|
| Ventilators, Mechanical | 1 | 2023 | 35 | 0.050 |
Why?
|
| Pandemics | 2 | 2022 | 1099 | 0.050 |
Why?
|
| Complement System Proteins | 1 | 2023 | 57 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 62 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2022 | 78 | 0.050 |
Why?
|
| Germ Cells | 1 | 2023 | 194 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 1882 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2025 | 693 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 280 | 0.050 |
Why?
|
| Immunization | 1 | 2022 | 307 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 332 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 295 | 0.040 |
Why?
|
| Data Collection | 1 | 2022 | 382 | 0.040 |
Why?
|
| Biopsy | 1 | 2024 | 1237 | 0.040 |
Why?
|
| Graft vs Host Disease | 1 | 2024 | 544 | 0.040 |
Why?
|
| Microcirculation | 1 | 2020 | 94 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 180 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2022 | 542 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1267 | 0.040 |
Why?
|
| Communication | 1 | 2022 | 507 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2022 | 848 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 197 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2022 | 770 | 0.040 |
Why?
|
| Lung | 1 | 2024 | 1491 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1140 | 0.030 |
Why?
|
| Weibel-Palade Bodies | 1 | 2015 | 1 | 0.030 |
Why?
|
| Models, Immunological | 1 | 2015 | 35 | 0.030 |
Why?
|
| Complement C3 | 1 | 2015 | 48 | 0.030 |
Why?
|
| Clonal Evolution | 1 | 2015 | 40 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2015 | 88 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 2818 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2024 | 12324 | 0.030 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2014 | 7 | 0.030 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2014 | 20 | 0.030 |
Why?
|
| Medical Records | 1 | 2015 | 189 | 0.030 |
Why?
|
| Animals | 2 | 2020 | 34088 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 1052 | 0.030 |
Why?
|
| Time Factors | 1 | 2022 | 6293 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2015 | 1496 | 0.020 |
Why?
|
| United States | 1 | 2025 | 10891 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 2154 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3554 | 0.020 |
Why?
|